Status:
COMPLETED
Mirtazapine for Chronic Insomnia in Older Adults
Lead Sponsor:
Centre hospitalier de l'Université de Montréal (CHUM)
Collaborating Sponsors:
Quebec Researchnetwork on aging
Conditions:
Chronic Insomnia
Eligibility:
All Genders
65+ years
Phase:
PHASE1
Brief Summary
Insomnia is highly prevalent in the older adult population. The pharmacolgical management of chronic insomnia includes benzodiazepines and Z-drugs (zolpidem, zopiclone). Although these drugs are indic...
Eligibility Criteria
Inclusion
- Age 65 years and older
- A report of sleep initiation or maintenance problems
- An adequate opportunity and circumstances to sleep,
- To have at least one daytime consequence in relation to sleep complaint.
- Sleep disorder and daytime consequences occur at least 3 times a week.
- Duration of sleep disorder and daytime consequences for at least 3 months
- Sleep complaint cannot be explained by a sleep disorder other than chronic insomnia.
Exclusion
- Contrindication to mirtazapine
- Use of drug for insomnia
- Cognitive Behavioural Therapy for insomnia
- Use of Melatonin
- Active psychiatric illness
- Parkinson's disease
- Major Neurocognitive disorders
- More than one fall in the last 3 months
Key Trial Info
Start Date :
October 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 30 2024
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT05247697
Start Date
October 1 2022
End Date
July 30 2024
Last Update
August 12 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Hospitalier de l'Université de Montréal
Montreal, Quebec, Canada, H2X0C1